Calcitonin delivery

Serres, A., M. Baudys, and S.W. Kim, Temperature and pH-sensitive polymers for human calcitonin delivery. Pharmaceutical Research, 1996.13(2) 196-201. 

Thysman, S., C. Hanchard, and Y. Preat. 1994. Human calcitonin delivery in rats by iontophoresis. J Pharm Pharmacol 46 725. 

Garcia-Fuentes, M., Prego, C., Torres, D., Alonso, M., 2005. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly (ethylene glycol) as carriers for oral calcitonin delivery. European Journal of Pharmaceutical Sciences 25, 133-143. 

A review is presented on the controlled release of calcitonins from polymeric matrices and oil-based formulations covering the period 1992-8. Polymers covered include biodegradable polymers, such as polyglycolic acid, polylactic acid and copolymers thereof, and non-biodegradable polymers, such as styrene-isopropyl acrylamide copolymers and poly(methacrylic acid-g-ethylene glycol) copolymers, for oral calcitonin delivery systems. 28 refs. 

The absorption of drugs from the rectal [32] cavity has been studied in some detail. Muranishi et al. [34] have shown that a significant increase in the absorption and lymphatic uptake of soluble and colloidal macromolecules can be achieved by pretreating the rectal mucosal membrane with lipid-nonionic surfactant mixed micelles. They found no evidence of serious damage of the mucosal membrane. Davis [30] suggested that the vaginal cavity could be an effective delivery site for certain pharmaceuticals, such as calcitonin, used for the treatment of postmenopausal osteoporosis. 

The Ca2+ -responsive conformationally changeable membrane may be a good model of a new drug-delivery system, where calcitonin or parathyloid hormone can be released for the homeostasis of serum Ca2+ level. 

Sinko PJ, Lee YH, Makhey V, Leesman GD, Sutyak JP, Yu H, Perry B, Smith CL, Hu P, Wagner EJ, Falzone LM, Mcwhorter LT, Gilligan JP and Stern W (1999) Biopharmaceutical Approaches for Developing and Assessing Oral Peptide Delivery Strategies and Systems In Vitro Permeability and In Vivo Oral Absorption of Salmon Calcitonin (Set). Pharm Res 16 pp 527-533. 

Richardson, J.L., and Armstrong, T.I., Vaginal Delivery of Calcitonin by Hyaluronic Acid Formulations. In Bioadhesive Drug Delivery Systems (E. Mathiowitz, D.E. Chickering, III, and C.-M. Lehr, eds.), Marcel Dekker, Inc., New York, 1999, pp. 563-599. 

The stability of a suspension-emulsion of benzimidazole in oil was evaluated by quantifying the fractions of polymorphs A, B, and C as soon as prepared and after one year using a calibration model developed using pure polymorph samples [233]. The concentrations of mannitol in its amorphous form and each of three polymorphs were determined within 5% mass fraction, relative to salmon calcitonin [234]. The powders all were sized for delivery by respiration, less than 5 tan. 

Parenteral calcitonin (32 aa) formulations are used to regulate calcemia. Intranasal delivery of calcitonin, a potentially convenient alternative, produces low bioavailability and is not useful as such. Permeation enhancers, including mixed micelle formulations composed of either... 

Elorek, T.A. Christensen, and M.R. Hill, Intrapulmonary drug delivery of salmon calcitonin. Calcif Tissue Int, 1997. 61(4) 345-7. 

Morimoto, K., Katsumata, H., Yabuta, T., et al. (2000). Gelatin microspheres as a pulmonary delivery system Evaluation of salmon calcitonin absorption. J. Pharm. Pharmacol., 52, 611-617. 

Sakuma, S., Suzuki, N., Sudo, R., Hiwatari, K.-I., Kishida, A., Akashi, M. (2002). Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin. International Journal of Pharmaceutics, 239, 185-195. 

Shah, R.B., A. Palamakula, and M.A. Khan. 2004. Cytotoxicity evaluation of enzyme inhibitors and absorption enhancers in Caco-2 cells for oral delivery of salmon calcitonin. J Pharm Sci 93 1070. 

Guggi, D., A.H. Krauland, and A. Bernkop-Schnurch. 2003. Systemic peptide delivery via the stomach in vivo evaluation of an oral dosage form for salmon calcitonin. J Control Release 92 125. 

Transmucosal delivery of salmon calcitonin (sCT) via the buccal route was studied using a mucoadhesive bilayer thin-film composite (TFC) [104], In vitro studies showed that over 80% of sCT was released from the TFCs within 240 min. The relative bioavailability for rabbits treated with the film composites was 43.8% + 10.9% as compared to intravenous injection. 

Cui, Z., and R.J. Mumper. 2002. Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites. Pharm Res 19 1901. 

Rochira, M., et al. 1996. Novel vaginal delivery systems for calcitonin. II. Preparation and characterization of HYAFF microspheres containing calcitonin. Int J Pharm 144 19. 

In the past, calcitonin was administered by injection (intramuscular or subcutaneous), but aerosolized versions of calcitonin are now available that allow delivery in the form of nasal sprays.51,68 Oral delivery of calcitonin is difficult because this hormone is absorbed poorly from the gastrointestinal (GI) tract and because calcitonin is degraded by proteolytic enzymes in the stomach.57 Nonetheless, efforts are being made to overcome these limitations, and an oral form of calcitonin may be available someday.62... 

Lee YH, Sinko PJ. Oral delivery of salmon calcitonin. Adv Drug Deliv Rev. 2000 42 225-238. 

L. J. Deftos, and A.K. Banga. 2000. Transdermal iontophoretic delivery of salmon calcitonin. Int.J. Pharm. 200 107-113. 

---